{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:36Z","timestamp":1792801956608,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-113-088"],"award-info":[{"award-number":["DMR-113-088"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2314-B-039-032"],"award-info":[{"award-number":["MOST110-2314-B-039-032"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2628-B-039-005"],"award-info":[{"award-number":["MOST110-2628-B-039-005"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04336-9","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:30:43Z","timestamp":1772019043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse"],"prefix":"10.1007","volume":"75","author":[{"given":"Chi-Hsien","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhen-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ze","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yueh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ling","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-2566","authenticated-orcid":false,"given":"KS Clifford","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-3233","authenticated-orcid":false,"given":"Kevin Chih-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"25","key":"4336_CR1","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377(25):2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"key":"4336_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3577","author":"SK Subudhi","year":"2020","unstructured":"Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q et al (2020) Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz3577","journal-title":"Sci Transl Med"},{"issue":"5","key":"4336_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4336_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79419-3","volume":"10","author":"KC Huang","year":"2020","unstructured":"Huang KC, Chiang SF, Chen TW, Chen WT, Yang PC, Ke TW et al (2020) Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2\/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Sci Rep 10(1):22330. https:\/\/doi.org\/10.1038\/s41598-020-79419-3","journal-title":"Sci Rep"},{"key":"4336_CR5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18693.1","author":"HM Maeng","year":"2019","unstructured":"Maeng HM, Berzofsky JA (2019) Strategies for developing and optimizing cancer vaccines. F1000Research. https:\/\/doi.org\/10.12688\/f1000research.18693.1","journal-title":"F1000Research"},{"issue":"5","key":"4336_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","volume":"27","author":"L Zheng","year":"2021","unstructured":"Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL et al (2021) Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin Cancer Res 27(5):1278\u20131286. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2974. (2nd)","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4336_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"4336_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1098344","volume":"14","author":"SR Niavarani","year":"2023","unstructured":"Niavarani SR, St-Cyr G, Daniel L, Lawson C, Giguere H, Alkayyal AA et al (2023) Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer. Front Immunol 14:1098344. https:\/\/doi.org\/10.3389\/fimmu.2023.1098344","journal-title":"Front Immunol"},{"issue":"11","key":"4336_CR9","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17(11):3520\u20133526. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3126","journal-title":"Clin Cancer Res"},{"issue":"10427","key":"4336_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403(10427):632\u2013644. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7","journal-title":"Lancet"},{"issue":"1","key":"4336_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","volume":"6","author":"AM Keeler","year":"2019","unstructured":"Keeler AM, Flotte TR (2019) Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol 6(1):601\u2013621. https:\/\/doi.org\/10.1146\/annurev-virology-092818-015530","journal-title":"Annu Rev Virol"},{"key":"4336_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00202-19","author":"ZA Mekonnen","year":"2019","unstructured":"Mekonnen ZA, Grubor-Bauk B, English K, Leung P, Masavuli MG, Shrestha AC et al (2019) Single-dose vaccination with a hepatotropic adeno-associated virus efficiently localizes T cell immunity in the liver with the potential to confer rapid protection against Hepatitis C Virus. J Virol. https:\/\/doi.org\/10.1128\/JVI.00202-19","journal-title":"J Virol"},{"issue":"4","key":"4336_CR13","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C et al (2019) Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6(4):e230\u2013e239. https:\/\/doi.org\/10.1016\/S2352-3018(19)30003-7","journal-title":"Lancet HIV"},{"key":"4336_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.omtm.2023.03.010","volume":"29","author":"AC Franke","year":"2023","unstructured":"Franke AC, Hardet R, Prager L, Bentler M, Demeules M, John-Neek P et al (2023) Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. Mol Ther Methods Clin Dev 29:238\u2013253. https:\/\/doi.org\/10.1016\/j.omtm.2023.03.010","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"4336_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","volume":"29","author":"N Zabaleta","year":"2021","unstructured":"Zabaleta N, Dai W, Bhatt U, Herate C, Maisonnasse P, Chichester JA et al (2021) An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe 29(9):1437\u201353 e8. https:\/\/doi.org\/10.1016\/j.chom.2021.08.002","journal-title":"Cell Host Microbe"},{"issue":"1","key":"4336_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01158-w","volume":"7","author":"S Zhao","year":"2022","unstructured":"Zhao S, Ke J, Yang B, Tan F, Yang J, Lin CP et al (2022) A protective AAV vaccine for SARS-CoV-2. Signal Transduct Target Ther 7(1):310. https:\/\/doi.org\/10.1038\/s41392-022-01158-w","journal-title":"Signal Transduct Target Ther"},{"key":"4336_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.omtm.2023.01.006","volume":"28","author":"K Krotova","year":"2023","unstructured":"Krotova K, Kuoch Yoshitomi H, Caine C, Aslanidi G (2023) Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model. Mol Ther Methods Clin Dev 28:301\u2013311. https:\/\/doi.org\/10.1016\/j.omtm.2023.01.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4336_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.omto.2019.10.001","volume":"15","author":"K Krotova","year":"2019","unstructured":"Krotova K, Day A, Aslanidi G (2019) An engineered AAV6-based vaccine induces high cytolytic anti-tumor activity by directly targeting DCs and improves Ag presentation. Mol Ther Oncolytics 15:166\u2013177. https:\/\/doi.org\/10.1016\/j.omto.2019.10.001","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"4336_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/icb.2013.74","volume":"92","author":"J Pandya","year":"2014","unstructured":"Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G (2014) Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol 92(2):116\u2013123. https:\/\/doi.org\/10.1038\/icb.2013.74","journal-title":"Immunol Cell Biol"},{"key":"4336_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber T (2021) Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol 12:658399. https:\/\/doi.org\/10.3389\/fimmu.2021.658399","journal-title":"Front Immunol"},{"key":"4336_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3438","author":"YK Chan","year":"2021","unstructured":"Chan YK, Wang SK, Chu CJ, Copland DA, Letizia AJ, Costa Verdera H et al (2021) Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd3438","journal-title":"Sci Transl Med"},{"issue":"1","key":"4336_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1084-4","volume":"38","author":"L Aurisicchio","year":"2019","unstructured":"Aurisicchio L, Salvatori E, Lione L, Bandini S, Pallocca M, Maggio R et al (2019) Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. J Exp Clin Cancer Res 38(1):78. https:\/\/doi.org\/10.1186\/s13046-019-1084-4","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4336_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0644-7","volume":"7","author":"A Lopes","year":"2019","unstructured":"Lopes A, Feola S, Ligot S, Fusciello M, Vandermeulen G, Preat V et al (2019) Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. J Immunother Cancer 7(1):174. https:\/\/doi.org\/10.1186\/s40425-019-0644-7","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4336_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10594-2","volume":"10","author":"AM D'Alise","year":"2019","unstructured":"D\u2019Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I et al (2019) Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat Commun 10(1):2688. https:\/\/doi.org\/10.1038\/s41467-019-10594-2","journal-title":"Nat Commun"},{"issue":"1","key":"4336_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J et al (2020) An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 11(1):1395. https:\/\/doi.org\/10.1038\/s41467-020-15229-5","journal-title":"Nat Commun"},{"issue":"11","key":"4336_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1652539","volume":"8","author":"E Tondini","year":"2019","unstructured":"Tondini E, Arakelian T, Oosterhuis K, Camps M, van Duikeren S, Han W et al (2019) A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology 8(11):1652539. https:\/\/doi.org\/10.1080\/2162402X.2019.1652539","journal-title":"Oncoimmunology"},{"issue":"7963","key":"4336_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618(7963):144\u2013150. https:\/\/doi.org\/10.1038\/s41586-023-06063-y","journal-title":"Nature"},{"issue":"7738","key":"4336_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234\u2013239. https:\/\/doi.org\/10.1038\/s41586-018-0792-9","journal-title":"Nature"},{"issue":"1","key":"4336_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/2326-6066.CIR-22-0318","volume":"11","author":"KC Huang","year":"2023","unstructured":"Huang KC, Lai CY, Hung WZ, Chang HY, Lin PC, Chiang SF et al (2023) A novel engineered AAV-based neoantigen vaccine in combination with radiotherapy eradicates tumors. Cancer Immunol Res 11(1):123\u2013136. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0318","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4336_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00881-5","volume":"9","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chen WT, Chen JY, Lee CY, Wu CH, Lai CY et al (2024) Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers. NPJ Vaccines 9(1):95. https:\/\/doi.org\/10.1038\/s41541-024-00881-5","journal-title":"NPJ Vaccines"},{"issue":"1","key":"4336_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01132-x","volume":"10","author":"TW Ke","year":"2025","unstructured":"Ke TW, Chen CY, Chen WT, Tsai YY, Chiang SF, Huang CH et al (2025) Targeting B7-H3 enhances the efficacy of neoantigen-based cancer vaccine in combination with radiotherapy. NPJ Vaccines 10(1):80. https:\/\/doi.org\/10.1038\/s41541-025-01132-x","journal-title":"NPJ Vaccines"},{"key":"4336_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138740","author":"C Lhuillier","year":"2021","unstructured":"Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L et al (2021) Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI138740","journal-title":"J Clin Invest"},{"key":"4336_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"key":"4336_CR34","doi-asserted-by":"publisher","first-page":"54040","DOI":"10.3791\/54040","volume":"114","author":"AV Paschall","year":"2016","unstructured":"Paschall AV, Liu K (2016) An orthotopic mouse model of spontaneous breast cancer metastasis. J Vis Exp 114:54040. https:\/\/doi.org\/10.3791\/54040","journal-title":"J Vis Exp"},{"issue":"12","key":"4336_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/2326-6066.CIR-15-0089","volume":"3","author":"C Voena","year":"2015","unstructured":"Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B et al (2015) Efficacy of a cancer vaccine against ALK-rearranged lung tumors. Cancer Immunol Res 3(12):1333\u20131343. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0089","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"4336_CR36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","volume":"4","author":"I Mota","year":"2023","unstructured":"Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E et al (2023) ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer 4(7):1016\u20131035. https:\/\/doi.org\/10.1038\/s43018-023-00591-2","journal-title":"Nat Cancer"},{"issue":"7","key":"4336_CR37","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.34382","volume":"152","author":"C Sun","year":"2023","unstructured":"Sun C, Nagaoka K, Kobayashi Y, Maejima K, Nakagawa H, Nakajima J et al (2023) Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. Int J Cancer 152(7):1463\u20131475. https:\/\/doi.org\/10.1002\/ijc.34382","journal-title":"Int J Cancer"},{"key":"4336_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","volume":"25","author":"JR Mendell","year":"2022","unstructured":"Mendell JR, Connolly AM, Lehman KJ, Griffin DA, Khan SZ, Dharia SD et al (2022) Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol Ther Methods Clin Dev 25:74\u201383. https:\/\/doi.org\/10.1016\/j.omtm.2022.02.011","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"4336_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/gt.2015.89","volume":"23","author":"R Sayroo","year":"2016","unstructured":"Sayroo R, Nolasco D, Yin Z, Colon-Cortes Y, Pandya M, Ling C et al (2016) Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther 23(1):18\u201325. https:\/\/doi.org\/10.1038\/gt.2015.89","journal-title":"Gene Ther"},{"issue":"4","key":"4336_CR40","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.21037\/tlcr-19-633","volume":"9","author":"Q Li","year":"2020","unstructured":"Li Q, Ma W, Chen S, Tian EC, Wei S, Fan RR et al (2020) High integrin \u03b13 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res 9(4):1361\u20131378. https:\/\/doi.org\/10.21037\/tlcr-19-633","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"4336_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","volume":"27","author":"J Jou","year":"2021","unstructured":"Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW (2021) The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification. Clin Cancer Res 27(3):689\u2013703. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0245","journal-title":"Clin Cancer Res"},{"key":"4336_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.omtm.2023.02.009","volume":"28","author":"UT Hacker","year":"2023","unstructured":"Hacker UT (2023) On the way to developing AAV-based vaccines as novel tools for cancer immunotherapy. Mol Ther Methods Clin Dev 28:394\u2013395. https:\/\/doi.org\/10.1016\/j.omtm.2023.02.009","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"4336_CR43","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1128\/IAI.01274-08","volume":"77","author":"ML Leong","year":"2009","unstructured":"Leong ML, Hampl J, Liu W, Mathur S, Bahjat KS, Luckett W et al (2009) Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect Immun 77(9):3958\u20133968. https:\/\/doi.org\/10.1128\/IAI.01274-08","journal-title":"Infect Immun"},{"issue":"32","key":"4336_CR44","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF et al (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29(32):5203\u20135209. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.025","journal-title":"Vaccine"},{"issue":"9653","key":"4336_CR45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","volume":"372","author":"MJ McElrath","year":"2008","unstructured":"McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H et al (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653):1894\u20131905. https:\/\/doi.org\/10.1016\/S0140-6736(08)61592-5","journal-title":"Lancet"},{"issue":"6","key":"4336_CR46","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21(6):704\u2013712. https:\/\/doi.org\/10.1089\/hum.2009.182","journal-title":"Hum Gene Ther"},{"issue":"1","key":"4336_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00483-z","volume":"7","author":"JC Flickinger Jr.","year":"2022","unstructured":"Flickinger JC Jr., Staudt RE, Singh J, Carlson RD, Barton RJ, Baybutt TR et al (2022) Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. NPJ Vaccines 7(1):61. https:\/\/doi.org\/10.1038\/s41541-022-00483-z","journal-title":"NPJ Vaccines"},{"issue":"6","key":"4336_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112599","volume":"42","author":"RA Ramirez-Valdez","year":"2023","unstructured":"Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM et al (2023) Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Rep 42(6):112599. https:\/\/doi.org\/10.1016\/j.celrep.2023.112599","journal-title":"Cell Rep"},{"key":"4336_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004022","author":"M Xiao","year":"2022","unstructured":"Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z et al (2022) CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4336_CR50","doi-asserted-by":"publisher","DOI":"10.1051\/bmdcn\/2018080104","volume":"8","author":"X Wang","year":"2018","unstructured":"Wang X, Sheu JJ, Lai MT, Yin-Yi Chang C, Sheng X, Wei L et al (2018) RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. Biomedicine 8(1):4. https:\/\/doi.org\/10.1051\/bmdcn\/2018080104","journal-title":"Biomedicine"},{"key":"4336_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008515","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chiang SF, Chang HY, Hong WZ, Chen JY, Lee PC et al (2024) Colorectal cancer-specific IFN\u03b2 delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-008515","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4336_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46254-1","volume":"13","author":"KC Huang","year":"2023","unstructured":"Huang KC, Ke TW, Chen JY, Hong WZ, Chiang SF, Lai CY et al (2023) Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. Sci Rep 13(1):19440. https:\/\/doi.org\/10.1038\/s41598-023-46254-1","journal-title":"Sci Rep"},{"issue":"9","key":"4336_CR53","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1002\/jcp.30323","volume":"236","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Yang PC, Ke TW, Chen TW, Lin CY et al (2021) ATAD3A stabilizes GRP78 to suppress ER stress for acquired chemoresistance in colorectal cancer. J Cell Physiol 236(9):6481\u20136495. https:\/\/doi.org\/10.1002\/jcp.30323","journal-title":"J Cell Physiol"},{"issue":"7","key":"4336_CR54","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00262-023-03416-4","volume":"72","author":"YS Lin","year":"2023","unstructured":"Lin YS, Chiang SF, Chen CY, Hong WZ, Chen TW, Chen WT et al (2023) Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation. Cancer Immunol Immunother 72(7):2283\u20132297. https:\/\/doi.org\/10.1007\/s00262-023-03416-4","journal-title":"Cancer Immunol Immunother"},{"key":"4336_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061218","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Yang PC, Ke TW, Chen TW, Hu CH et al (2021) Immunogenic cell death by the novel topoisomerase I inhibitor TLC388 enhances the therapeutic efficacy of radiotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13061218","journal-title":"Cancers (Basel)"},{"key":"4336_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 17:10\u201312. https:\/\/doi.org\/10.14806\/ej.17.1.200","journal-title":"EMBnet J"},{"issue":"5","key":"4336_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491\u2013498. https:\/\/doi.org\/10.1038\/ng.806","journal-title":"Nat Genet"},{"issue":"3","key":"4336_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568\u2013576. https:\/\/doi.org\/10.1101\/gr.129684.111","journal-title":"Genome Res"},{"issue":"1","key":"4336_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"issue":"2","key":"4336_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W (2015) HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2):166\u2013169. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638","journal-title":"Bioinformatics"},{"issue":"12","key":"4336_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"issue":"3","key":"4336_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, Wollam AT et al (2020) Pvactools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res 8(3):409\u2013420. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0401","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4336_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1989790","volume":"10","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Ke TW, Chen TW, Hu CH, Yang PC et al (2021) DNMT1 constrains IFN\u03b2-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. Oncoimmunology 10(1):1989790. https:\/\/doi.org\/10.1080\/2162402X.2021.1989790","journal-title":"Oncoimmunology"},{"issue":"1","key":"4336_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06408-5","volume":"15","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chiang SF, Lin PC, Hong WZ, Yang PC, Chang HP et al (2024) TNF\u03b1 modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer. Cell Death Dis 15(1):24. https:\/\/doi.org\/10.1038\/s41419-023-06408-5","journal-title":"Cell Death Dis"},{"issue":"5","key":"4336_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03692-8","volume":"73","author":"JY Chen","year":"2024","unstructured":"Chen JY, Lin PY, Hong WZ, Yang PC, Chiang SF, Chang HY et al (2024) Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy. Cancer Immunol Immunother 73(5):92. https:\/\/doi.org\/10.1007\/s00262-024-03692-8","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4336_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33927-5","volume":"8","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chiang SF, Ke TW, Chen TW, You YS, Chen WT et al (2018) Clinical significance of programmed death 1 ligand-1 (CD274\/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Sci Rep 8(1):15658. https:\/\/doi.org\/10.1038\/s41598-018-33927-5","journal-title":"Sci Rep"},{"issue":"1","key":"4336_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07912-6","volume":"16","author":"JY Chen","year":"2025","unstructured":"Chen JY, Ke TW, Chiang SF, Hong WZ, Chang HY, Liang JA et al (2025) CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer. Cell Death Dis 16(1):584. https:\/\/doi.org\/10.1038\/s41419-025-07912-6","journal-title":"Cell Death Dis"},{"key":"4336_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218132","volume":"637","author":"YY Tsai","year":"2026","unstructured":"Tsai YY, Chang HY, Hong WZ, Chen JY, Chiang SF, Lin YS et al (2026) Targeting DRP1 promotes radiotherapy-induced antitumor immunity via mitochondrial DNA-mediated cGAS-STING signaling in KRAS-mutated colorectal cancer. Cancer Lett 637:218132. https:\/\/doi.org\/10.1016\/j.canlet.2025.218132","journal-title":"Cancer Lett"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04336-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:30:44Z","timestamp":1772019044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04336-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4336"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04336-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}